Search Results - "Pivkova, A"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    PB2343 INDIVIDUALIZED TREATMENT AGAINST BACTERIAL INFECTIONS IN STEM CELL RECIPIENTS ‐ SINGLE CENTER EXPERIENCE by Stojanoski, Z., Pivkova, A., Panovska‐Stavridis, I., Cadievski, L., Georgievski, B., Ivanovski, M., Karanfilski, O., Cevreska, L.

    Published in HemaSphere (01-06-2019)
    “…Background: Multidrug resistant (MDR) bacteria are increasingly frequent in HSCT recipients, but significant differences in etiology of bacterial infections…”
    Get full text
    Journal Article
  10. 10

    The Relationship between Naloxone Dose in the Treatment of a Non-fatal Heroin Overdose by Chaparoska, D, Pivkova, A

    Published in Clinical toxicology (Philadelphia, Pa.) (01-05-2007)
    “…Objectives: To examine the relationship between patient variables and variation in naloxone dose (from standard dose of 2 mg IV) administered in the hospital…”
    Get full text
    Journal Article
  11. 11

    Acute myeloblastic leukaemia in donors of PBSC for allogeneic transplantation--Case report by Georgievski, B, Stavrik, S. Genadieva, Stojanoski, Z, Pivkova, A

    Published in Bone marrow transplantation (Basingstoke) (01-03-2009)
    “…Allogeneic transplantation from HLA identical family donor is a common therapeutic approach in patients with intermediate risk AML in first CR. We present an…”
    Get full text
    Journal Article
  12. 12

    Iron overload in patients with transfusion dependent myelodisplastic syndrome by Genadieva-Stavrik, S, Georgievski, B, Stojanoski, Z, Krstveska-Balkanov, S, Pivkova, A, Trajkova, M, Genadieva-Dimitrova, M, Serafimoski, V

    “…The myelodisplastic syndrome is a heterogeneous group of diseases, characterised by ineffective and dysplastic haematopoesis and pancytopenia in the peripheral…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Stem cell transplantation - new treatment approaches by Stojanoski, Z, Georgievski, B, Pejkov, H, Pivkova, A, Cevreska, L, Genadieva-Stavrik, S, Milenkov, V, Dukovski, R, Kotevski, V

    “…Stem cell research still remains one of the most controversial fields of science today on account cell plasticity and its capability of transdifferentiation or…”
    Get full text
    Journal Article
  16. 16

    Autologous stem-cell transplantation in patients with multiple myeloma by Stojanoski, Z, Georgievski, B, Cevreska, L, Stojanovic, A, Pivkova, A, Genadieva-Stavric, S, Stankovic, S, Karadzova-Stojanoska, A

    “…- Multiple myeloma is a malignant plasma-cell proliferative disorder, the second most common haematologic cancer. Treatment with high-dose therapy (HDT) and…”
    Get full text
    Journal Article
  17. 17

    Intermediate VP-16 (1gr/[m.sup.2]) plus G-CSF (10 mcg/kg) or cyclophosphamide (3gr/[m.sup.2]) plus G-CSF (10mcg/kg) for progenitor cell mobilisation in lymphoma patients by Georgievski, B, Milenkov, V, Stavrik, S. Genadieva, Stojanoski, Z, Pivkova, A, Cevreska, L, Karanfilski, O

    Published in Bone marrow transplantation (Basingstoke) (01-03-2009)
    “…Cyclophosphamide (CTX) 3gr/[m.sup.2] plus G-CSF 10mcg/[m.sup.2] is commonly used regimen for mobilization of peripheral blood progenitor cells (PBPC) to…”
    Get full text
    Journal Article
  18. 18

    Intermediate VP-16 for progenitor cell mobilisation in lymphoma patients by Pivkova, A, Stavrik, S. Genadieva, Stojanoski, Z, Cevreska, L, Karanfilski, O, Milenkov, V, Georgievski, B

    Published in Bone marrow transplantation (Basingstoke) (01-03-2009)
    “…Cyclophosphamide (CTX) 3gr/[m.sup.2] plus G-CSF 10mcg/[m.sup.2] is commonly used regimen for mobilization of peripheral blood progenitor cells (PBPC) to…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Gram-positive bacterial predomination in stem-cell transplant recipients by Stojanoski, Z, Cevreska, L, Genadieva-Stavrik, S, Pivkova, A, Ivanovski, N, Petrovska, M, Popovska, K, Georgievski, B

    Published in Bone marrow transplantation (Basingstoke) (01-03-2009)
    “…Background: Infections are the most common complications of stem cells transplantation and chemotherapy induced neutropenia. Bacterial infections predominate…”
    Get full text
    Journal Article